NVS - Conatus And Emricasan: The Moment
"Success is the result of perfection, hard work, learning from failure and persistence" - Colin Powell
Background
The conclusion to the 20-year persistence by inventors, Drs. Mento and Spada, to establish the clinical value of emricasan (IDN-6556, PF-03491390) in liver diseases is imminent. Conatus Pharmaceuticals (CNAT) is a small cap ($151M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative Phase 2b drug candidate. The imminent catalyst is the top-line data readout for NASH cirrhotic severe portal hypertension ((PH)) in Q4 2018.
Briefly, PH also known as